We support you throughout the entire machine life cycle, from spare parts management to digital line optimization. Service agreements are a key element of our portfolio structure. Together, we tailor our solutions to your individual needs. Our global network of experts supports you with maintenance planning, technical support, and modernizations, as well as operator training and end of life services. With our digital solutions, you gain control over your production processes and create transparency on product and machine data anytime, anywhere.
Continuous manufacturing in Pharma
Continuous manufacturing is changing oral solid dosage (OSD) production. Higher flexibility, shorter development times with minimum API usage, and a direct transfer from development to production without scale-up are among the primary requirements of pharmaceutical manufacturers. In continuous manufacturing, the processes occur one after the other without interruption while the product is charged and discharged simultaneously. The main challenge with traditional solutions is the precise dosing of the starting materials in a constant mass flow rate of milligrams per second.
Syntegon is tackling the challenges in continuous manufacturing with a different approach, called Xelum.
Continuous Manufacturing from Syntegon: Xelum
Continuous manufacturing is changing oral solid dosage (OSD) production. Higher flexibility, shorter development times with minimum API usage, and a direct transfer from development to production without scale-up are among the primary requirements of pharmaceutical manufacturers.
Why choose continuous manufacturing?
Watch the video to learn more.
OSD: Many facets – one partner
Oral solid dose (OSD) manufacturing is a demanding endeavor. There is no better partner to tackle those tasks with than Syntegon. Our OSD services and process technology will make your production a rock-solid success. Find out more in this video.
Xelum: The fastest way to continuous manufacturing
The Xelum platform doses active ingredients and excipients as discrete masses and not as a continuous mass flow. This way, even smallest amounts of APIs of less than 1% can be dosed precisely. The system doses, mixes and granulates individual packages, so-called X-keys, which continuously run through the process chain and are discharged successively as granules, tablets, or capsules.
Unique and proven technology
The Xelum platform is based on the robust and proven fluid bed processors that Syntegon has been refining for over 30 years. They cover granulation and drying in the same process chamber. This eliminates the need to transfer wet granulate, benefitting the system’s reliability. Xelum achieves high granulation yields with the desired characteristics – including unimodal particle size distribution, as well as excellent flow and tableting properties. The platform further ensures lower production costs and high flexibility. The same holds true for the Xelum R&D and pilot unit, your point of entry into continuous manufacturing.
Our Xelum R&D is your ideal start into continuous manufacturing.
Since it uses exactly the same components as the Xelum production platform, process parameters can be directly transferred 1:1 without scale-up. This is valid for dosing, blending, and granulation. You can develop formulations for both batch and continuous manufacturing on the same machine, starting from 250 g. Xelum R&D can run clinical trial and pilot batches at a rate of 10 kg/h. The user-friendly controls of the system is complemented by a practical, automated DoE support. As a fully contained unit, it is also perfectly suited for the development of high potent APIs.
Xelum production line
If you are looking for a continuous production line with a small footprint, flexibility and fast product changeovers, look no further!
Our Xelum production unit uses only 1/3 of the production space of a comparable batch production, saving important cleanroom space, reducing energy costs drastically. The modular set-up allows you to integrate tableting and capsuling. Next to fluid bed granulation also other processes like direct compression are possible. All process parameters can be transferred 1:1 from the Xelum R&D since both machines share the exactly the same components. This eliminates the need for time and cost-intensive scale-up. With a nominal throughput of 30 kg/h, it is an ideal companion for your pilot and production-scale manufacturing.
Features of our continuous manufacturing technology
Our simplified process concept includes smart controls that keep your process within specification. They eliminate the need for complex measurement technology while ensuring consistently high product quality.
Use case scenarios
Outstanding granule quality
Whether you compress granules into tablets or fill them into capsules or sachets, e.g. for nutraceuticals – our Xelum achieves outstanding quality for any dosage form.
Tablets at their best
Outstanding granule properties like smooth flowability and an ideal particle size distribution result in excellent compression characteristics – even at very low API concentration, e.g. for cancer therapy.
Yes we capsule
Granules, pellets and mini tablets are perfectly suitable for fixed-dose or personalized combination capsules, e.g. anti-infective drugs. Our Xelum ensures optimum quality of the individual components.
Technical data of our continuous manufacturing technology
|Nominal throughput (kg/h)||0.25 ro 10||30|
|At a density of (kg/l)||0.5||0.5|
Why choose a Syntegon Xelum for continuous manufacturing?
Oral solid dosage forms (OSD) are our specialty: in the course of our long business history, we have supported countless industry players across the globe and shared our rich expertise in tablet coating. As an innovation-driven company, we are far from maintaining the status quo: over the last few years, we have been actively pursuing new ways to advance OSD manufacturing. Download our selection of brochures to find out more.
Syntegon enters strategic parnership with Bayer
The cooperation is based on the Xelum platform developed by Syntegon's subsidiary Hüttlin, which both partners intend to advance together and establish as a standard for continuous production in the pharmaceutical industry.
Shanghai Pharmaceuticals and Syntegon partner to promote continuous manufacturing in China
Shanghai Pharmaceuticals and Syntegon have signed an agreement to build a laboratory for continuous manufacturing technology in China. The cooperation will promote the application of this new technology, shorten development cycles of new drugs, reduce the cost of drug development, continuously improve the accessibility of new (especially orphan) drugs in China, and create more value for patients.